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Abstract 
Liposomes from octadecyl-(1,1-dimethyl-4-piperidino-4-yl)-phosphate (OPP), a new alkylphospholipid derivative with an 
improved cancerostatic a tivity, were prepared for the first time and the activity in vitro and in vivo was characterised. The 
formation of liposomes (MLV, SUV and LUVET) differing in cholesterol content, charge, and sterical stabilisation is 
possible without serious problems, despite the lysolipid-like structure of the OPP. Liposomes with a low amount of 
cholesterol and with PEG2000DSPE-coating were the most stable OPP liposomes, both in buffer and in serum. The 
cytotoxicity of micellar or liposomal OPP against breast cancer cell lines in vitro was in the range of 20-60 IxM. The 
cytotoxicity of the liposomal formulation was inversely related to the content of cholesterol, whereas the sterical stabilisation 
and/or the incorporation of a positive charge had only a very moderate modulating effect on the inhibition of cell 
proliferation. The strongest antitumour effect on the xenotransplanted breast cancer MT-3 in vivo was obtained with 
sterically stabilised OPP liposomes with low CH content. The beneficial therapeutic effect of these liposomes was 
accompanied by better tolerance and a significant inhibition of haemolysis compared to micellar OPP. © 1998 Elsevier 
Science B.V. All rights reserved. 
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1. Introduction 
Abbreviations: APC, alkylphosphocholine; CH, cholesterol; 
DCP, dicetylphosphate; DDAB, dimethyl-dioctadecylammonium 
bromide; HPC, hexadecylphosphocholine; IC50, concentration f
drug required to inhibit cell growth by 50%; LUVET, large uni- 
lamellar vesicle made by extrusion technique; MLV, multilamel- 
lar vesicles; OPP, octadecyl-(1,1-dimethyl-piperidino-4-yl)-phos- 
phate; PBS, phosphate-buffered saline solution; PEG, 
polyethyleneglycol; PEG2000DSPE, N-(O-methyl-polyethylenglyc- 
yl)-l,2-distearyl-s,n-glycero-3-phosphoethanol-amine; RES, retic- 
uloendothelial system; SUV, small unilamellar vesicle 
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Successful treatment of  high-incidence breast can- 
cer is still a serious problem. The search for new 
therapeutic strategies, or the improvement of 'classi- 
cal' treatment approaches, therefore remains chal- 
lenging. One promising new group of drugs without 
DNA interaction consists of  ether- and alkylphos- 
pholipids, because the cell membrane is used as a 
target for therapeutic ntervention. These compounds 
are especially effective against breast cancer in vitro 
[1,2] and in vivo [3,4], as well as for the clinical treat- 
ment of  metastases [5]. 
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A serious, dose-limiting side effect of these lipids is 
haemolysis, which can be prevented if the lipids are 
used in liposomal form [6,7], although this is prob- 
ably accompanied by a reduction in therapeutic ac- 
tivity, as has been shown at least in vitro [2]. 
A second advantage in the use of liposomal 
vesicles is the variability of preparation methods 
leading to liposomes with different pharmacological 
behaviour. 
Based on our experiences with hexadecylphos- 
phocholine and its analogues with various chain 
lengths, we wanted to investigate the newly devel- 
oped octadecyl-(N,N-dimethyl-piperidino-4-yl)-phos- 
phate (OPP, Perifosine, D21266, Fig. 1), which had 
recently been reported to have an improved activity 
against DMBA-induced mammary tumours of the 
rat [8]. 
The aim of this study was to compare the antitu- 
mour activity of OPP and HPC in a panel of four 
different human breast cancer cell lines. Further- 
more, and more importantly, we were interested in 
finding liposomal preparations with cytostatic activ- 
ity similar to micellar OPP, but with all the advan- 
tages of liposomes in vivo. 
This study focused on the influence of the compo- 
sition, especially with regard to cholesterol content, 
charge, size and sterical stabilisation on the physical 
properties and on the cytotoxic effect in vitro, as well 
as on the therapeutic activity in vivo. 
2.1. Liposome preparation and characterisation 
MLV at a concentration of 10 mM were prepared 
by the lipid film/hydration method from appropriate 
mixtures of stock solutions of the components in 
CH2Clz/MeOH, (7:3, v/v). The resuspension of the 
lipid film in PBS or calcein containing water (30 
mM) resulted in plain or marker entrapping MLV. 
LUVET were prepared from these MLV as described 
previously [9] by repeated extrusion through polycar- 
bonate filters (diameter of pores, 100 nm) using a 
LiposoFast Basic System (Avestin, Ottawa, Canada) 
until the suspensions were unimodal. In some cases, 
it was additionally necessary to sonicate the vesicles 
to obtain a unimodal liposomal population (see Ta- 
ble 1). Vesicle size determination was performed by 
dynamic light-scattering measurement with a Coulter 
Counter N4 MD model and the AccuComp System 
from Coulter Electronics (Hialeah, USA). Size is ex- 
pressed in nm as unimodal mean diameter +S.D. and 
size distribution as polydispersity index (PI) - vary- 
ing from 0 (entirely monodisperse) to 1 (completely 
polydisperse suspension). 
All the concentrations for liposomes reported here 
in this study are based on the concentration of the 
active OPP and were determined by HPTLC meas- 
urements. 
2.2. Stability of liposomes 
2. Materials and methods 
N- (O- Methyl-polyethylenglycyl)- 1,2 distearyl-s,n- 
glycero-3-phosphoethanol-amine, Na-salt (PEG2000- 
DSPE) with about 45 repetitive thoxy-units were 
purchased from Sygena (Liestal, Switzerland). OPP 
and HPC were a generous gift from Dr. Hilgard 
(ASTA Medica, Frankfurt, Germany). Dicetylphos- 
phate (DCP), cholesterol (CH) and calcein were pur- 
chased from Serva (Heidelberg, Germany). CH was 
recrystallised from acetone prior to use. Triton X-100 
was a product of Ferak (Berlin, Germany). CH2C12 
and MeOH from Merck (Darmstadt, Germany) were 
used in Lichrosolv gradient grade quality. PBS and 
foetal calf serum (FCS) are products of Gibco, Life 
Technologies (Eggersstein, Germany). 
2.2.1. Buffer stability 
Three batches of each liposome preparation with 
encapsulated calcein (30 mM) were prepared imme- 
diately after the separation of the liposomes from 
unencapsulated calcein by gel chromatography (Se- 
phadex G50) and by diluting the liposomes to about 
100 nmol/ml with PBS buffer. The suspensions were 
stored at 4°C until measurement. 
At appropriate time points 100 ~tl/well of these 
liposome dilutions were applied to a 96-well micro- 
titre plate (Maxisorp black, Nunc, Kamstrup Den- 
mark) in triplicate. The amount of released calcein 
was directly determined by fluorescence measure- 
ments at Fex 485 nm and Fem 510 nm with a SLT 
Fluostar plate reader (TECAN, Crailsheim, Ger- 
many) and calculated from a standard curve. The 
total amount of encapsulated calcein was determined 
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in a similar way after destruction of the liposomes by 
adding 50 ~tl of Triton X-100 to each well. 
2.2.2. Serum stability 
Two different liposome preparations were diluted 
with a 50% mixture of foetal calf serurn/PBS to a 
concentration of 100 ~tM in duplicate and stored 
for different periods of time at 20°C. The solutions 
(each 100 ~tl) were measured for calcein quantifica- 
tion with the SLT Fluostar plate reader as described 
above. 
2.3. Cell growth inhibition experiments in vitro 
Human breast cancer cell lines MT-1 and MT-3 
[10], MaTu [11], SKBR3 (ATCC, Parklawn, USA), 
all oestrogen receptor negative, were cultured in 
RPMI-1640 medium (Gibco) or McCoy's 5A me- 
dium (SKBR3) and supplemented with 2 ~tmol/ml 
L-glutamine (Flow Labs), penicillin G (100 U/ml), 
streptomycin (100 ~tg/ml, both from Gist-Brocades) 
and heat-inactivated foetal calf serum, (10% FCS, 
Gibco). All the reagents were free of endotoxin con- 
taminations. 
Cells in the exponential growth phase were seeded 
in a density of 1 X 105/ml in a 96-well microtitre plate 
(Falcon) on the day before the start of the incubation 
with the drug. Liposomal and free drug were serially 
diluted with medium to a concentration between 200 
and 12.5 pM and given to the cells for 24 h in trip- 
licate. Cells were then washed twice with PBS before 
fresh medium with MTT (0.5 mg/ml) was added for 
further 4 h of incubation. Finally, 190 ~tl of the 
supernatant was carefully removed, the formed for- 
mazan completely resolved in isopropanol-HC1, fol- 
lowed by 10 min of shaking. The quantification of 
the formazan was done by absorption measurements 
using a SLT-plate reader (TECAN, Crailsheim, 
Germany) at 530 nm. The percentage inhibition 
was calculated in relation to the growth of 
control cells handled similar, but without drug expo- 
sure. 
The ICs0 data were determined from the growth 
inhibition curves for each individual experiment and 
given as mean_ S.D. of at least four independent 
experiments. 
2.4. In vivo experiments 
Female NCR nu/nu mice, weighing 18-24 g, were 
used for the investigation. They were maintained 
under standardised (24°C, 50% humidity) sterile con- 
ditions, received sterile bedding and food (Sniff, 
Svest, Germany) and acidified drinking water. 
All animal experiments were performed in accord- 
ance with the Animal Welfare and Ethics Rules li- 
censed by the Senate of Berlin (Number G0090/94). 
2.4.1. Therapeutic experiment 
Pieces of the MT-3 human breast cancer with a 
size of 2-3 mm diameter were transplanted s.c into 
the left flank of eight anaesthetised mice/group. 
Treatment with micellar OPP or different OPP-LU- 
VET (each 25 mg/kg/day) or saline (control) started 
when tumours were palpable (4-5 mm diameter) and 
was done i.p. on days 11-15 and 18-22 after tumour 
transplantation. Size of the tumours was measured 
twice/week with callipers. Tumour volume was calcu- 
lated as follows: width 2 x length/2. Median tumour 
volume is given as relative tumour volume (RTV) 
calculated for each measurement in relation to the 
starting tumour volume at the first treatment day. 
The percentage of RTV of treated to control group 
(T/C %) is used for characterisation f drug activity. 
Lethality and body weight change were determined 
as toxicity parameters. 
2.4.2. Determ&ation of the haemolytic activity in vivo 
Female NCR nu/nu mice were injected i.p. with 
100 mg/kg OPP in micellar or liposomal formulation 
(6 mice/group). After 1 h, blood was taken from the 
retro-orbital venous plexus. The obtained serum was 
diluted 1:5 with PBS and its extinction was measured 
at 540 nm. The extinction was correlated with the 
haemoglobin content in the serum. 
2.5. Statistics 
Statistical comparisons for in vitro data were per- 
formed with the unpaired Student's t-test (two pop- 
ulations) and with the Mann-Whitney non-paramet- 
ric test for in vivo results. Differences were 
considered to be significant at P < 0.05. 
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3. R ~  
Liposomes were prepared for the first time from 
OPP and DCP (negatively charged) or DDAB (pos- 
itively charged) at a ratio of 10:2, with a cholesterol 
content between 27.8 and 45.5°/'0 of the total lipids 
(this corresponds to a molar ratio of OPP/charged 
compound/CH between 10:2:5 and 10:2:10). In 
view of the therapeutic experiments in vivo, we addi- 
tionally added PEG2000DSPE (10 mol% of OPP) to 
some compositions to obtain sterically stabilised lip- 
osomes. 
3.1. Physical properties of OPP liposomes 
/ 
Fig. 1. Basic structure of alkylphospholipids. 
Positively charged MLV were found to be more 
heterogeneous than negatively charged MLV and 
had a broader size distribution as indicated by the 
standard eviation and the PI (Table 1). 
Small liposomes (LUVET) with a mean diameter 
between 100 and 200 nm were prepared from MLV 
by the extrusion technique. Whereas both 10:10 
compositions (OPP/CH; Negl0, Posl0; for abbrevi- 
ations and composition in detail see Table 1) were 
extruded without any problem, this method was in- 
creasingly hindered with decreasing CH content of 
the liposomes. MLV with a molar ratio of 10:5 
(OPP/CH) could only be converted to small vesicles 
by sonication, and not by extrusion. 
This difference between 10:10 LUVET (control 
liposomes) and vesicles with a lower CH content 
was additionally confirmed by the increased mean 
size, as well as by the higher polydispersity index 
of the liposomes. All of these preparations were 
more heterogeneous than the control liposomes. 
The LUVET were investigated for their stability in 
aqueous ystems at 5°C for 4 months (Fig. 2). The 
Table 1 
Characterization of OPP-liposomes 
Type Name Composition (molar ratio) a OPP/CH (% of total lipid) Size (nm) b PI c Marker (mmol/mol) a 
LUVET Negl0 e 10:10:2:0 45.5/45.5 103.0+9.5 0.122 83.07+4.41 
Neg7.5 10:7.5:2:0 51.3/38.5 135.0+49.1 0.287 67.75+3.73 
Neg5 10:5:2:0 58.8/29.4 125.4+45.3 0.280 29.23 + 1.18 
Neg5P 10:5:2:1 55.6/27.8 133.6 +46.1g 0.239 39.38_+4.59 
Posl0 f 10:10:2:0 45.5/45.5 108.8 _+ 28.4 0.097 86.87 _+ 3.36 
Pos7.5 10:7.5:2:0 51.3/38.5 186.5 -+ 77.5g 0.557 77.95_+13.7 
Pos5 10:5:2:0 58.8/29.4 104.4 + 44.9g 0.176 20.91 _+ 1.46 
Pos5P 10:5:2:1 55.6/27.8 126.5_+47.7 0.335 37.15+2.09 
MLV Negl0 10:10:2:0 45.5/45.5 324.5+114.2 0.737 n.d. 
Negl0P 10:10:2:1 43.5/43.5 620.6+282.8 0.915 n.d. 
Posl0 10:10:2:0 45.5/45.5 473.5+208.9 0.878 n.d. 
Posl0P 10:10:2:1 43.5/43.5 354.4+ 149.7 0.629 n.d. 
~Liposomal composition OPP-CH-x-PEG2000DSPE where x is a charged component. 
bUnimodal results, mean + S.D. for three measurements. 
CPolydispersity index, calculated from unimodal results of size determination by DLS spectroscopy. 
dEncapsulated fluorescence marker calcain, given is the amount of calcein/liposomal OPP. 
eNeg: charged component x is dicetylphosphate. 
fPos: charged component x is dioctadecyl-dimethylamine bromide (DDAB). 
gObtained after sonication. 
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Fig. 2. Stability of OPP-liposomes after storage in buffer. Lipo- 
somes (about 100 laM) of different compositions (for details ee 
Table l) were stored in PBS buffer at 5°C for 4 months. Re- 
lease of encapsulated calcein (absolute amounts are given in Ta- 
ble 1) was determined byfluorescence measurement at Fex 495 
nm/Fem 510 nm as described in Section 2. The mean release of 
marker for three different liposome samples compared to total 
amount isgiven in percent (+ S.D.). 
and with a stronger final release after more than 
2 days (Fig. 3A). 
The liposomes with a 10:10 composition exhibited 
the highest absolute and percentage release. After 
about 50 h of incubation, for example (Fig. 3B), 
more than 2000 pmol/ml marker were released by 
Negl0 and Posl0 liposomes. This corresponds to 
63.4 and 83.1% of total marker, respectively. 
The reduction of cholesterol decreased the release 
of marker. The preparations with only 50% CH con- 
tent were the most stable liposomes, with the release 
of an absolute amount smaller than 800 pmol/ml. 
The incorporation of PEG2000DSPE resulted in addi- 
tional stabilisation. Thus, Pos5P-liposomes released 
39.5%, the Neg5P-liposomes only 32.9% of the total 
encapsulated marker (Fig. 3A,B). Comparing the 
data with other incubation times results in a similar 
gradation of the influence of composition, as we have 
demonstrated here for this long time incubation. 
3.2. Cytotoxic effects in vitro 
release of the fluorescence marker calcein was de- 
pendent on the charge and the cholesterol content 
as well. All positively charged liposomes released 
more marker than the negatively charged ones. The 
reduction of the amount of CH improved the stabil- 
ity, this was more pronounced for the positively 
charged liposomes than for the negatively charged 
ones. The three preparations with the highest release 
of more than 35% of encapsulated marker were 
Posl0, Pos7.5 and Pos5. All the other liposomes ex- 
hibited very similar stability, with a maximum release 
of only 10-15% (Fig. 2). 
The stability of the liposomes in serum was inves- 
tigated by incubation of calcein encapsulating 
vesicles in PBS/foetal calf serum (1/1, v/v) mixtures 
for at least 6 days, followed by fluorescence measure- 
ments of the released marker (Fig. 3). The same time 
dependency asdescribed earlier [9] was found, with a 
fast release within the first minutes, followed by a 
plateau phase with only a marginal additional release 
After summarizing all the data, we determined cy- 
totoxicity, expressed as the concentration necessary 
to inhibit the cell growth to 50% (IC50), to be in the 
range of 20-100 ~tM for an incubation of 105 cells/ml 
for 24 h (Fig. 4). Micellar OPP was significantly bet- 
ter than HPC in 3 of 4 cell lines. The IC50 data 
determined in the SKBR3 cell system were the high- 
est for all investigated cell systems (Fig. 4). 
For MT1 and SKBR3 we found again the effect 
already known from HPC liposomes. The liposomal 
preparations with a high cholesterol content (Negl0, 
Posl0) were significantly less toxic (P < 0.05) to the 
cells than the micellar compound (Fig. 5). In con- 
trast, MaTu and MT3 were found to be similarly 
sensitive to OPP and OPP liposomes, independent 
of the composition. 
The reduction of CH increased the cytotoxic effect 
against all cell lines investigated in this study and 
resulted in lower IC50 data. In the MT1 and 
SKBR3 cell model, 6 of 12 liposomal preparations 
Fig. 3. Stability of OPP-liposomes after incubation i serum. Two different liposome preparations of each composition were incubated 
in 50% foetal calf serum/PBS (100 ~M). The samples were measured after appropriate imes in duplicate as described in Fig. 2. The 
amount of released marker is given as mean of two measurements each done in duplicate. (A) Time course for the release of calcein. 
(B) Influence of composition on marker release, given in percent of total encapsulated calcain (mean +S.D.) after a storage of 54 h 
(indicated by the arrow in A). 
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Fig. 4. Influence of liposomal composition on cytotoxicity in vitro. IC50 data for different breast cancer cell lines are given in part in 
all four panels. Cells were incubated with different liposomes for 24 h in triplicate as described in Section 2. Data given are the mean 
of four independent experiments. *Significantly different o OPP (P < 0.05). 
with a reduced CH content were similarly as effective 
as OPP (Fig. 4, bars without , ;  P > 0.05). 
The incorporation of PEG2000DSPE for sterical 
stabilisation, or the use of DDAB as a charged com- 
ponent, had no or only a very weak influence on 
cytotoxicity as shown by comparing liposomes with 
similar CH content (Fig. 4). 
A comparison of LUVET and MLV to determine 
the influence of liposome type showed the latter to be 
significantly less toxic (P< 0.05) to all the cell lines 
Table 2 
Pharmacological ctivity of OPP in micellar or liposomal formulation in breast carcinoma xenograft MT-3 
Formulation Dose (mg/kg/day) a Toxic death/total number of mice T/C b (%) Body weight change (%) 
OPP 25 0/8 66 -5  
Negl0 c 25 0/8 46 -4  
Neg7.5 25 0/8 63 -7  
Neg5 25 1/8 77 -7  
Neg5P 25 0/8 23 d -3  
ai.p., on days 11-15 and 18-22 after tumour transplantation. 
bT/C: treated to control tumour size (on day 29 after tumour transplantation). 
CFor composition see Table 1. 
dSignificantly different o OPP (P < 0.05). 
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Fig. 5. Influence of liposomal composition on haemolysis in 
vivo. Female NCR nu/nu mice were injected i.p. with 100 mg/ 
kg micellar or liposomal OPP. One hour later, the extinction of 
serum was measured at 540 nm as described in Section 2. The 
percentage increase in haemolysis compared to saline treated 
control group as mean + S.D. of six mice is given. *Significantly 
different o micellar OPP (P > 0.05). 
investigated. The MLV were also significantly less 
cytotoxic than the micellar OPP (P<0.001; data 
not shown). 
3.3. Therapeutic experiments in vivo 
OPP in micellar and liposomal formulations was 
tested in an oestrogen receptor negative breast xeno- 
graft (MT-3). This model was chosen because of the 
remarkable antitumour activity of APL, especially in 
breast carcinomas [6,8,10]. In the experiment pre- 
sented in Table 2, liposomes with different cholester- 
ol content and sterical stabilisation were compared to 
micellar OPP. Clearly, the PEG-containing liposomes 
showing the highest stability and the lowest IC50 in 
vitro, exerted the most pronounced inhibition of tu- 
mour growth in vivo. The other liposomal prepara- 
tions were, like OPP, only moderately active in this 
experiment, which was due to the relatively low dose 
used (25 mg/kg). Both lethality and body weight were 
unaffected or only marginally changed, respectively. 
Fig. 5 presents the extinction of serum 1 h after 
administration of OPP in micellar or different lipo- 
somal formulations as an indication of the haemo- 
lytic potential of the amphiphilic ompound. Clearly, 
micellar OPP and Negl0 liposomes led to a distinct 
induction of haemolysis, while all other preparations 
only marginally increased the haemoglobin content 
in the serum. 
4. Discussion 
Hilgard et al. [8] recently described a new alkyl- 
phospholipid erivative. These lipids are well known 
for their antitumour activity against a number of 
tumours in vitro and in vivo [1,12], and especially 
against oestrogen receptor negative mammary carci- 
nomas [3,6]. In the new lipid OPP, the choline head 
group is substituted by the cyclic aliphatic piperidyl 
residue (Fig. 1). The marginal modification in struc- 
ture changed the sterical properties lightly and led 
to an enhancement of the positive charge at nitrogen, 
compared to choline derivatives. This change re- 
sulted in a clear increase in the cytotoxic activity in 
vitro as compared to HPC, the main representative 
of the APL family, as demonstrated in this study and 
by Hilgard et al. [8]. 
The application of HPC and other APL in micellar 
form in vivo is accompanied by serious side effects, 
like haemolysis and gastrointestinal toxicity [4,13]. 
Haemolysis was also observed in our experiment us- 
ing micellar OPP. The use of OPP liposomes instead 
of the micellar alkylphospholipid reduced both side 
effects as demonstrated earlier for HPC liposomes 
[4,7]. 
The aim of this study was, then, to characterise 
liposomes prepared for the first time from this new 
APL and to optimise the liposomal formulation with 
regard to stability and pharmacological properties. 
Liposomes prepared so far from HPC were found 
to be less cytotoxic in vitro than the micellar solution 
of similar concentration [2]. 
OPP-MLV and vesicles of a defined, small size 
(LUVET with a diameter < 200 nm) with different 
amounts of CH, with a negative or positive charge, 
and in some cases with sterical stabilisation by PEG 
coating, were prepared and investigated for the first 
time. 
The liposomes were first characterised for their 
physical properties. The vesicle formation was very 
similar to that seen for alkylphosphocholine lipo- 
somes. But in contrast to our former impression 
[2], that a molar ratio of 1:1 for alkylphosphocho- 
line/CH seems to be necessary to obtain stable lip- 
osomes, it was found in the present study that a 
reduction of the CH content o 50 mol% is possible 
with still continued vesicle formation. 
There was no problem with negatively charged lip- 
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osomes, even after the addition of PEG2000DSPE, 
one of the most frequently used compounds to 
achieve sterical stabilisation [14], as could be shown 
by size characterisation as well as for stability meas- 
urements in an aqueous ystem and in serum. If the 
charged component DCP was substituted by the pos- 
itive compound DDAB, the situation became more 
complicated. The aggregation sometimes een after 
MLV preparation and the decreased stability in 
buffer clearly indicated a stronger disorder of the 
membrane than found for negatively charged 
vesicles. It was demonstrated recently [15] that the 
incorporation of more than 3 mol% of a single 
positively charged compound resulted in a more fluid 
liposomal membrane. This probably explains the low 
stability of the positively charged liposomes in buffer 
compared to the negatively charged ones, because the 
amount of DDAB used was always higher than 8.7 
mol%. 
The situation in serum was different from that in 
PBS. Vesicles with similar composition, but different 
charge, exhibited similar stability. The release was 
only related to the content of CH in the membrane. 
Interestingly, the stability based on the release 
data was found to increase with decreasing CH con- 
tent. Usually, the contrary would be expected be- 
cause the decrease in CH is accompanied with a re- 
duction of membrane fluidity [16,17]. We assume 
that the single chain lipid OPP requires an optimum 
amount of cholesterol to stabilise the membrane 
maximally, which seems to be achieved better with 
a ratio of 2:1 than 1 : 1 for OPP/CH. 
Summarizing these data, the best liposomal prep- 
arations with regard to physical properties were 
found to be the liposomes Neg5, Neg5P or Pos5P. 
In the next step, we were interested in the effects of 
the different preparations against umour cells in vi- 
tro. The cells used in our experiment showed differ- 
ent sensitivity to micellar and liposomal OPP, indi- 
cating different mechanisms for the binding or 
uptake. 
We first investigated the effect of cholesterol on 
cytotoxicity in vitro. It is known that cholesterol in 
liposomal preparations sometimes have a diminish- 
ing effect on the cancerostatic activity when lipo- 
somes are used as carriers for classical anticancer 
drugs [18,19]. Our data demonstrated that the incor- 
poration of a high amount of CH reduced the cyto- 
toxicity compared to micellar OPP for all the inves- 
tigated cell lines. In contrast, the reduction of 
liposomal cholesterol correlates with an increase of 
the cytotoxic effect in vitro. This could be explained 
by the increase in membrane fluidity caused by CH 
reduction [17,20], which probably facilitates (specific) 
interactions between components of the liposomal 
membrane with those of the cellular membrane. 
But these findings are only partially consistent with 
the in vivo results described previously [20], which 
demonstrated that the uptake of liposomes by tu- 
mour cells is not dependent on the content of CH 
and thus on the fluidity of the membrane, but is 
related to the size of liposomes. Size dependency ex- 
plains, on the other hand, the decreased cytotoxic 
activity found for the large OPP-MLV, most likely 
by an inhibition of the trans-bilayer t ansport of the 
MLV into the cells. 
The increase in cytotoxicity with decreasing lipo- 
somal CH could also be the result of a release of 
micellar OPP from the vesicles or the destruction of 
the liposomes. But both the differences in cell sensi- 
tivity to micellar and liposomal OPP found for differ- 
ent cell lines, and the high stability in serum of OPP- 
LUVET with a lower amount of CH, made such an 
explanation relatively unlikely. Nevertheless, more 
experiments are necessary to explain these observa- 
tions. 
The incorporation of the positively charged com- 
pound DDAB, instead of DCP, had no modulating 
effect on the inhibition of growth in the cells inves- 
tigated. DDAB seems to be well-tolerated by the cells 
used. 
It still remains unclear why sterically stabilised lip- 
osomes (Neg5P and Pos5P) showed similar in vitro 
activity as liposomes of the same composition, but 
without pegylation (Neg5 and Pos5). Taking into 
account hat there is a specific uptake by the cells, 
and that the hydrophilic chains of the PEG lipids 
cover the liposomes, the more or less specific lipo- 
some-cell interaction should be reduced for the pe- 
gylated liposomes, similar to the situation demon- 
strated recently for macrophages ([9,21], for review 
see [14]). This indicates a different mechanism for 
liposome uptake by macrophages and breast umour 
cells, as has also been discussed when comparing 
CV1 green monkey kidney cells with J774 macro- 
phage-like cells [22]. To our knowledge, it is not 
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yet known whether the sterical stabilisation generally 
affects liposome-cell interaction or if a specific pre- 
vention of l iposome recognition and uptake only by 
macrophages i  obtained. 
Based on the in vitro results, small, sterically sta- 
bilised liposomes with a reduced content of CH 
should be the most active liposomal formulation in 
vivo. This could be confirmed in the animal experi- 
ments. OPP induced only a moderate, and not sig- 
nificant, inhibition of tumour growth in a human 
xenograft breast cancer model at the relatively low 
and tolerable dose of 25 mg/kg/day administered i.p. 
The intraperitoneal route of  administration chosen 
for these experiments resulted in better tolerance of 
the drugs used compared to the i.v. route and pre- 
vented the destruction of  the liposomes after oral 
application. No side effects were observed in the peri- 
toneum. 
The antitumour effect could be improved remark- 
ably when OPP was administered in a stable PEG- 
containing liposomal formulation with a reduced CH 
content. In addition, the haemolytic potential of  al- 
kylphospholipids demonstrated with micellar OPP 
could be prevented if OPP was applied in liposomal 
form. The best tolerance was found for Neg5P-lip- 
osomes. 
It could be shown in this study that an improve- 
ment of the therapeutic index of the new alkylphos- 
pholipid OPP is possible if it is used in liposomal 
form. The careful selection of the properties of  these 
OPP liposomes (especially concerning composition 
and size) increases the stability as well as the activity 
in vitro. The human MT-3 xenotransplanted breast 
cancer model revealed that the best l iposomal formu- 
lation found in vitro (Neg5P) was also the best prep- 
aration in vivo with regard to therapeutic activity 
and the reduction of haemolysis. 
OPP, even in liposomal form, is a powerful new 
alkylphospholipid erivative and the results of  the 
first ongoing clinical trials with micellar OPP are 
awaited with great anticipation. Independent of 
this, further improvement of the OPP should be pos- 
sible, especially in order to reduce side effects, if lip- 
osomal OPP, instead of  the micellar formulations, is 
used for further clinical applications. 
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